Table 4.
Predicted mean absolute LDL cholesterol lowering from baseline to week 12 with bempedoic acid–statin combination
| Mean LDL-C (mg/dL)a | ||||||||
|---|---|---|---|---|---|---|---|---|
| Atorvastatin | Simvastatin | Rosuvastatin | Pravastatin | |||||
| Statin dose (mg) | Alone | + BA 180 mg | Alone | + BA 180 mg | Alone | + BA 180 mg | Alone | + BA 180 mg |
| 0 | 183.1 | 132.7 | 183.1 | 132.7 | 183.1 | 132.7 | 183.1 | 132.7 |
| 10 | 116.2 | 89.6 | 129.0 | 99.6 | 98.2 | 79.5 | 143.4 | 108.6 |
| 20 | 104.0 | 84.0 | 117.7 | 92.5 | 87.8 | 72.6 | 136.2 | 104.3 |
| 40 | 94.2 | 77.5 | 106.3 | 86.0 | 79.0 | 67.6 | 124.6 | 96.9 |
| 80 | 84.2 | 70.6 | — | — | — | — | 115.9 | 90.3 |
BA, bempedoic acid; LDL-C, LDL cholesterol.
a
Data represent 1000 simulation subjects using unique parameter estimates.